BiTEs function by linking a T cell to a cancer cell via two distinct binding domains. One domain binds to the CD3 receptor on the T cell, while the other domain binds to a specific antigen on the cancer cell. This dual binding activates the T cell, triggering the release of cytotoxic substances that induce apoptosis in the cancer cell. This mechanism leverages the body's own immune system to fight cancer, offering a targeted therapeutic approach.
